Cuongma Index
liked
META's Earnings
$Meta Platforms (META.US)$' stock surged over 20% following the announcement of their better-than-expected earnings, forward guidance, and new initiatives for shareholder returns. This rally increased the company's market cap by nearly $200 billion, setting a record according to Bloomberg data. Meta shares, which had dipped as low as $90 in 2022,...
$Meta Platforms (META.US)$' stock surged over 20% following the announcement of their better-than-expected earnings, forward guidance, and new initiatives for shareholder returns. This rally increased the company's market cap by nearly $200 billion, setting a record according to Bloomberg data. Meta shares, which had dipped as low as $90 in 2022,...
+1
53
3
Cuongma Index
voted
$Singtel (Z74.SG)$ lai lai take your pick.
4
4
Cuongma Index
commented on
$Fullerton SGD Cash Fund(SG9999005961.MF)$ where is fund redeem button. why they keep changing UI?
1
5
Cuongma Index
voted
Spoiler:
At the end of this post, there is a chance for you to win points!
Happy Monday, mooers!
Welcome back to Weekly Buzz, where we review the news, performance, and community sentiment of the selected buzzing stocks on moomoo platform based on search and message volumes of last week (Nano caps are excluded).
Make Your Choices
Buzzing Stocks List & Mooers Comments
The major indices closed lower for the second consecutive week. The S&P 500 fell 2...
At the end of this post, there is a chance for you to win points!
Happy Monday, mooers!
Welcome back to Weekly Buzz, where we review the news, performance, and community sentiment of the selected buzzing stocks on moomoo platform based on search and message volumes of last week (Nano caps are excluded).
Make Your Choices
Buzzing Stocks List & Mooers Comments
The major indices closed lower for the second consecutive week. The S&P 500 fell 2...
60
56
Cuongma Index
liked
Goldman Upgrades Pfizer to Buy on Pipeline, New Launch Upside
Goldman Sachs analyst Chris Shibutani upgraded $Pfizer (PFE.US)$ to Buy from Neutral with a price target of $60, up from $47. Positive updates from the company's pipeline, and the potential for outperformance from the commercial new product launch portfolio over the course of the coming year, can drive "meaningful upside" to the value ascribed to Pfizer's base business, Shib...
Goldman Sachs analyst Chris Shibutani upgraded $Pfizer (PFE.US)$ to Buy from Neutral with a price target of $60, up from $47. Positive updates from the company's pipeline, and the potential for outperformance from the commercial new product launch portfolio over the course of the coming year, can drive "meaningful upside" to the value ascribed to Pfizer's base business, Shib...
14
1
better than monthly interest from the bank